Cuál es el precio por Aptose Biosciences Inc. (APS)

Precio por Aptose Biosciences Inc. (APS) es de$1.76

Cuál es la capitalización de mercado por Aptose Biosciences Inc. (APS)

Capitalización de mercado por Aptose Biosciences Inc. (APS) es $4.50M

Aptose Biosciences Inc. (APS) EPS

Aptose Biosciences Inc. is a clinical-stage biotechnology firm dedicated to discovering and advancing personalized therapeutic solutions for challenging oncology cases, primarily within the United States. Its robust pipeline features several key clinical programs: APTO-253, currently in Phase 1a/b trials, targets patients with relapsed or refractory blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS). Another candidate, HM43239, is undergoing Phase 1/2 evaluation for the treatment of relapsed or refractory AML. Aptose is also developing luxeptinib, which is in Phase 1a/b clinical studies for individuals battling relapsed or refractory B-cell malignancies, encompassing chronic lymphocytic leukemia, small lymphocytic lymphoma, various non-Hodgkin's lymphomas, as well as AML and HR MDS. Furthermore, the company is progressing with APL-581, a program centered on a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor. Aptose maintains strategic alliances with CrystalGenomics, Inc. and OHM Oncology. Incorporated in 1986 and headquartered in Toronto, Canada, the company was formerly known as Lorus Therapeutics Inc., changing its name to Aptose Biosciences Inc. in August 2014.

Año	EPS	Cambiar
Not enough data for the provided dates.

Año

EPS

Cambiar

Not enough data for the provided dates.

Empresa	EPS	Diferencia de EPS	País
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$13.70	-	BE

Empresa

EPS

Diferencia de EPS

País